


Data Sheet

WWW.UREIKO-CHEM.COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

Product Name :MK-0159
Cat.No. :URK-V2530
CAS No. : 2641484-61-7
Molecular Weight :400.49
Molecular Formula :C₂₀H₂₄N₄O₃S
Target :
Solubility :



Biological Activity

MK-0159, also known as Balixafortide, is a novel and selective antagonist of the chemokine receptor CXCR4. Balixafortide also has potential utility as a stem cell mobilizer. By disrupting the CXCR4-SDF1 axis, Balixafortide has been shown to mobilize hematopoietic stem cells into peripheral blood, making them more available for collection in patients undergoing stem cell transplantation.

References

1. Zhang Z, Ni C, Chen W. et al. Balixafortide (MK-0466) as a monotherapy or combination therapy with eribulin mesylate for the treatment of advanced breast cancer. *OncoTargets Ther.* 2020;13:393-401.
2. Ishikawa T, Nakashima S, Namba T. et al. Balixafortide, a CXCR4 antagonist, suppresses tumor progression and improves survival in a mouse model of pancreatic ductal adenocarcinoma. *Surg Today.* 2020 Oct;50(10):1224-1231.
3. Deng X, Ruan H, Zhang X. et al. Balixafortide, a CXCR4 antagonist, enhances the effect of chemotherapy and improves prognosis in advanced breast cancer patients. *Front Oncol.* 2020;10:43.
4. Fruehauf S, Seggewiss-Bernhardt R, Khandanpour C. et al. Balixafortide is a novel stem cell mobilizer with broad potential utility. *Blood.* 2018;132(Suppl 1):3034.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!

Caution: Product has not been fully validated for medical applications. Lab Use Only!

JACK@UREIKO-CHEM.COM